Παρακαλώ χρησιμοποιήστε αυτό το αναγνωριστικό για να παραπέμψετε ή να δημιουργήσετε σύνδεσμο προς αυτό το τεκμήριο: https://hdl.handle.net/10442/17394
Export to:   BibTeX  | EndNote  | RIS
Εξειδίκευση τύπου : Άρθρο σε επιστημονικό περιοδικό
Τίτλος: A triphenylphosphonium-functionalized mitochondriotropic nanocarrier for efficient co-delivery of doxorubicin and chloroquine and enhanced antineoplastic activity
Δημιουργός/Συγγραφέας: Panagiotaki K.N.
Sideratou Z.
Vlahopoulos S.A.
Paravatou-Petsotas M.
Zachariadis M.
Khoury N.
[EL] Ζουμπουρλής, Βασίλης[EN] Zoumpourlis, Vassilissemantics logo
Tsiourvas D.
Εκδότης: MDPI AG
Ημερομηνία: 2017
Γλώσσα: Αγγλικά
ISSN: 1424-8247
DOI: 10.3390/ph10040091
Περίληψη: Drug delivery systems that target subcellular organelles and, in particular, mitochondria are considered to have great potential in treating disorders that are associated with mitochondrial dysfunction, including cancer or neurodegenerative diseases. To this end, a novel hyperbranched mitochondriotropic nanocarrier was developed for the efficient co-delivery of two different (both in chemical and pharmacological terms) bioactive compounds. The carrier is based on hyperbranched poly(ethyleneimine) functionalized with triphenylphosphonium groups that forms ~100 nm diameter nanoparticles in aqueous media and can encapsulate doxorubicin (DOX), a well-known anti-cancer drug, and chloroquine (CQ), a known chemosensitizer with arising potential in anticancer medication. The anticancer activity of this system against two aggressive DOX-resistant human prostate adenocarcinoma cell lines and in in vivo animal studies was assessed. The co-administration of encapsulated DOX and CQ leads to improved cell proliferation inhibition at extremely low DOX concentrations (0.25 μM). In vivo experiments against DU145 human prostate cancer cells grafted on immunodeficient mice resulted in tumor growth arrest during the three-week administration period and no pervasive side effects. The findings put forward the potential of such targeted low dose combination treatments as a therapeutic scheme with minimal adverse effects.
Τίτλος πηγής δημοσίευσης: Pharmaceuticals
Τόμος/Κεφάλαιο: 10
Τεύχος: 4
Θεματική Κατηγορία: [EL] Βιολογία (Γενικά)[EN] Biology (General)semantics logo
Λέξεις-Κλειδιά: Chloroquine
Doxorubicin
Drug combinations
Drug delivery systems
Mitochondrial targeting
Old drugs
Poly(ethyleneimine)
Triphenylphosphonium cation
Αξιολόγηση από ομότιμους (peer reviewed): Ναι
Κάτοχος πνευματικών δικαιωμάτων: © 2017 by the authors. Licensee MDPI, Basel, Switzerland.
Όροι και προϋποθέσεις δικαιωμάτων: All Open Access, Gold, Green
Σημειώσεις: European Commission, EC; European Regional Development Fund, FEDER.
This work was partially supported by the project MIS 5002567 implemented under the “Action for the Strategic Development on the Research and Technological Sector”, funded by the Operational Programme “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020) and co-financed by Greece and the European Union (European Regional Development Fund). K.N.P. acknowledges financial support from the Greek State Scholarships Foundation from the program “Enhancement of human scientific resources through implementation of PhD research” with resources of the European program “Development of human resources, Education and lifelong learning”, 2014–2020, co-funded by the European Social Fund and Greek State.
Εμφανίζεται στις συλλογές:Ινστιτούτο Χημικής Βιολογίας - Επιστημονικό έργο

Αρχεία σε αυτό το τεκμήριο:
Το πλήρες κείμενο αυτού του τεκμηρίου δεν διατίθεται προς το παρόν από τον ΗΛΙΟ.